AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28752679
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (Control group)
Trial: 28752805
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs supplementation (1800 mg daily for 12 weeks, containing 1206 mg eicosapentaenoic acid and 609 mg docosahexaenoic acid)
Trial: 28753747
Drug: Degarelix therapy
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix therapy for 7 months
Trial: 28754494
Drug: CV7201 (mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly by needle-syringe or needle-free devices, doses ranging from 80-640 μg, with three doses and a booster after 1 year.
Trial: 28754494
Drug: CV7201 (mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly, doses of 80 μg or 160 μg intradermally and 200 μg or 400 μg intramuscularly.
Trial: 28754494
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of 80 μg CV7201 administered needle-free intradermally after 1 year.
Trial: 28754494
Drug: Intradermal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal or intramuscular needle-syringe injection of CV7201.
Trial: 28754534
Drug: Drug-eluting beads
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting beads loaded with doxorubicin (DEBDOX)
Trial: 28755389
Drug: Dulaglutide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 2.0 mg for 6 months
Trial: 28755389
Drug: Dulaglutide therapy
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide therapy
Trial: 28756183
Drug: Menaquinone-7 (vitamin
RxNorm normalized name: menaquinone-7 (vitamin K2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-7 (vitamin K2) supplementation (360 μg once daily) for 8 weeks
Trial: 28761581
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release, bilayer tablets for 7 consecutive days
Trial: 28761581
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release
Trial: 28761651
Drug: Self-adjusted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-adjusted medication during fasting
Trial: 28761685
Drug: Dual-therapy stent
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-therapy stent
Trial: 28761750
Drug: Aflibercept in
RxNorm normalized name: aflibercept Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Trial: 28761750
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Trial: 28762099
Drug: Multidisciplinary childhood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary childhood obesity treatment programme
Trial: 28763344
Drug: Desvenlafaxine 50-100
RxNorm normalized name: desvenlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 50-100 mg/day for 8 weeks
Trial: 28764748
Drug: Ganetespib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (150 mg/m) in combination with weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m)
Trial: 28764748
Drug: Ganetespib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (150 mg/m)
Trial: 28764836
Drug: Long-term aspirin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term aspirin treatment cessation before surgery
Trial: 28764836
Drug: Previous discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous discontinuation of aspirin treatment
Trial: 28764836
Drug: Unawareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unawareness of the reason for aspirin use
Trial: 28765502
Drug: Neoadjuvant 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant 5-fluorouracil (5-FU) 225 mg/m², oxaliplatin, and lapatinib in combination with radiation therapy
Trial: 28765502
Drug: Neoadjuvant 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant 5-fluorouracil (5-FU) in combination with radiation therapy
Trial: 28766535
Drug: ALL-2009 protocol
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALL-2009 protocol (non-intensive, continuous cytotoxic treatment)
Trial: 28768493
Drug: Supportive text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive text messages (twice-daily for 3 months)
Trial: 28768681
Drug: CALM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM therapy
Trial: 28768756
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg plus aspirin 325 mg (loading dose) followed by ticagrelor 90 mg BID plus aspirin 81 mg QD (maintenance therapy)
Trial: 28768822
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (1.0 g/kg every 3 weeks for up to 52 weeks)
Trial: 28769925
Drug: RO5459072, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5459072, a small molecule inhibitor of Cathepsin S
Trial: 28770543
Drug: Virtual-reality-based neurocognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual-reality-based neurocognitive stimulation sessions (20-min daily sessions)
Trial: 28771673
Drug: Single-agent lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-agent lenalidomide
Trial: 28771673
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice single-agent therapy
Trial: 28771889
Drug: Pralatrexate, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralatrexate, given i.v. weekly for 6 weeks of a 7-week cycle
Trial: 28771889
Drug: Concurrent vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent vitamin B, given alongside pralatrexate
Trial: 28772110
Drug: Luteinising hormone
RxNorm normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising hormone (LH)
Trial: 28772306
Drug: Lung adenocarcinoma
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung adenocarcinoma treatment, specific intervention details not available.
Trial: 28774277
Drug: Genomic variations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic variations in anthracycline metabolism and myocardial response to injury
Trial: 28778175
Drug: Dual-diagnosis motivational
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-diagnosis motivational interviewing (DDMI) and integrated group therapy (IGT)
Trial: 28778448
Drug: PF-00547659 anti-MAdCAM-1
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 anti-MAdCAM-1 therapy
Trial: 28778554
Drug: Integrated Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Care for patients with psychotic disorders (treatment for ≥4 years)
Trial: 28778611
Drug: Complete vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete vaccination cohort (2 doses of RV1)
Trial: 28778611
Drug: Incomplete vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incomplete vaccination cohort (1 dose of RV1)
Trial: 28778843
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus daily text message reminders for medication adherence
Trial: 28778843
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus 4 daily text messages for exercise adherence
Trial: 28778946
Drug: Subcutaneous electrocardiographic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous electrocardiographic monitors (St. Jude CONFIRM-AF) implanted in patients
Trial: 28780030
Drug: Lutonix 035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutonix 035 drug-coated balloon (DCB)
Trial: 28780401
Drug: Task-concurrent functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-concurrent functional connectivity dynamics
Trial: 28784593
Drug: Domiciliary VR-based
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domiciliary VR-based therapy
Trial: 28784593
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (home-based occupational therapy)
Trial: 28784598
Drug: Vorinostat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (100 mg twice daily) started on day -10 and continued through day +100 post-HCT with tacrolimus and methotrexate for GVHD prophylaxis.
Trial: 28784598
Drug: Vorinostat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (100 mg twice daily) with tacrolimus and methotrexate.
Trial: 28785295
Drug: ~60 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ~60 g/d almonds (ALM)
Trial: 28786339
Drug: Request for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Request for suspension or reduction in sentence on medical grounds (n=48)
Trial: 28786987
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch therapy for 24 weeks in patients with minimal WMHs (group 1)
Trial: 28786987
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch therapy for 24 weeks in patients with moderate WMHs (group 2)
Trial: 28786987
Drug: Discontinuation due
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation due to adverse events
Trial: 28787430
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and Docetaxel (G/D) window therapy
Trial: 28787430
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and Docetaxel (G/D)
Trial: 28789851
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (4th dose)
Trial: 28789851
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (3 doses)
Trial: 28790169
Drug: 6-month follow-up
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month follow-up understanding of warfarin and direct oral anticoagulants (DOACs)
Trial: 28790169
Drug: Understanding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Understanding of oral anticoagulant benefits at diagnosis
Trial: 28790169
Drug: Overall understanding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall understanding of AF treatment at 6 months
Trial: 28791297
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g omega-3 (OMACOR) daily
Trial: 28791628
Drug: Surgical approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical approach using mitomycin C (MMC) at a dose of 25 mg/m
Trial: 28791628
Drug: Percutaneous approach
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous approach using mitomycin C (MMC) at a dose of 25 mg/m
Trial: 28791698
Drug: Fenoterol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (180 µg) administered to OCT1-deficient individuals (n=5)
Trial: 28794078
Drug: SB4 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB4 (50 mg weekly subcutaneous administration)
Trial: 28794078
Drug: ETN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN (50 mg weekly subcutaneous administration)
Trial: 28794136
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum neutrophil gelatinase-associated lipocalin (sNGAL) levels in the last tertile (>220 ng/L)
Trial: 28794208
Drug: Increasing amounts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing amounts of chicken intake (from 88 to 290 g/d) over 3 weeks
Trial: 28794898
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination pill
Trial: 28795383
Drug: Integrated Imaginative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Imaginative Distention (IID) therapy, delivered as eight weekly training group sessions by a skilled psychotherapist.
Trial: 28796812
Drug: ONCOS-102 (Ad5/3-D24-GM-CSF)
RxNorm normalized name: ONCOSTATIN K
DrugBank: ONCOS-102 (DB17274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONCOS-102 (Ad5/3-D24-GM-CSF) administered by intracardial, intraperitoneal or subcutaneous injections
Trial: 28796812
Drug: Cyclophosphamide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide administered intraperitoneally twice a week
Trial: 28796812
Drug: NaCl solution
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaCl solution administered to control group
Trial: 28797193
Drug: Venetoclax monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax monotherapy (800-1200 mg)
Trial: 28797782
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy for cGVHD
Trial: 28798986
Drug: Tasquinimod (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasquinimod (0.5 mg/day for at least 2 weeks, increased to 1 mg/day)
Trial: 28800628
Drug: Sotalol 80mg
RxNorm normalized name: sotalol 80 MG
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sotalol 80mg oral dose
Trial: 28801186
Drug: Adjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant temozolomide (12 4-week cycles of 150-200 mg/m²) with radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy)
Trial: 28801477
Drug: Impaired renal
RxNorm normalized name: nut.tx.impaired renal fxn,soy ORAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired renal function (eCCl <60 mL/min)
Trial: 28801477
Drug: Both T2DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both T2DM and eCCl <60 mL/min
Trial: 28802168
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine (30µg)
Trial: 28802168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBV vaccine)
Trial: 28802255
Drug: Sym015, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym015, an antibody mixture composed of two humanized IgG
Trial: 28803122
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet of rosuvastatin 20 mg/ezetimibe 10 mg
Trial: 28803122
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of rosuvastatin 20 mg and ezetimibe 10 mg
Trial: 28803675
Drug: Fitness center
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitness center intervention (structured thrice weekly aerobic and resistance exercise program, supervised for the first 6 months)
Trial: 28804454
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy using a novel rehabilitation device
Trial: 28805662
Drug: CD30-specific chimeric
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts) infused at doses of 0.2 × 10^8 to 2 × 10^8 CD30.CAR-Ts/m2
Trial: 28805662
Drug: CD30-specific chimeric
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD30-specific chimeric antigen receptor T cells (CD30.CAR-Ts)
Trial: 28808360
Drug: Bemiparin (3500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemiparin (3500 IU anti-factor Xa, subcutaneous injection once daily)
Trial: 28808360
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg, subcutaneous injection once daily)
Trial: 28808443
Drug: Lisinopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (ACE inhibitor) for 1 week
Trial: 28808480
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy with modified EPIC regimen (etoposide, prednisolone, ifosfamide, cisplatin), median 3 cycles (range 1-6)
Trial: 28810177
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotic medications (SGAs)
Trial: 28810837
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg + Bevacizumab 7.5 mg/kg (DL1)
Trial: 28810837
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg + Bevacizumab 7.5 mg/kg (DL2)
Trial: 28810837
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg + Bevacizumab 10 mg/kg (DL3)
Trial: 28810837
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg + Bevacizumab 10 mg/kg (DL4)
Trial: 28810837
Drug: Pazopanib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (400 mg and 600 mg) pharmacokinetics
Trial: 28810904
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (AAD) - beta blockers (80.9% in previously diagnosed AF, 71.0% in newly diagnosed AF), calcium channel antagonists (24.0% in newly diagnosed AF).
Trial: 28810904
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (AAD) - class I (11.4%) and class III (9.1%) AADs.
Trial: 28810904
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers as rate control therapy.
Trial: 28810925
Drug: Surgical IPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical IPP with melphalan 30 mg/m²
Trial: 28810925
Drug: Percutaneous IPP
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous IPP with melphalan 30 mg/m²
Trial: 28813164
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity.
Trial: 28814281
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation hormone-therapy (NGHT)
Trial: 28814281
Drug: First generation
RxNorm normalized name: First generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First generation androgen deprivation therapy (Control)
Trial: 28814336
Drug: Shared injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shared injection drug solution
Trial: 28814336
Drug: Received used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received used drug injection equipment
Trial: 28814336
Drug: Shared solutions
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shared solutions
Trial: 28814336
Drug: Unsafe injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsafe injection risk
Trial: 28814336
Drug: Injection risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection risk behaviour
Trial: 28814412
Drug: Aflibercept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2.0 mg intravitreal injections
Trial: 29556416
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W)